Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $8,376,934
Primary Total: $5,743,215
Antineoplastic Effects of Suramin and Taxol on Human Thyroid Carcinoma, (427888), Lexington Clinic Fdtn for Medical Education, $50,000 (adjustment).
Human Thyroid Carcinoma Inhibition by Somatostatin, (427836), Natl Cancer Institute, $88,157 (adjustment).
*95-H&N-08- Phase II Trial: Taxol (Paclitaxel) 96-Hour Continuous Infusion for Any Stage Anaplastic Carcinoma of the Thyroid, (429650), Bristol Myers, $1.
Cholesterol Lowering Effects of Yogurt, (428707), MONA, $9,958 (adjustment).
A Six-week Cross-Over Study of the Effect of Beta-Glucan Versus Placebo on Serum Lipoproteins in Subjects with Primary Hypercholesterolemia, (428691), McNeil Specialty Products Company, $16,815
(adjustment). Cholesterol Lowering Effects of Lactobacillus Acidophillus in Rats, (428834), MONA, $8,000 (adjustment).
A 52 Week Study of the Weight Loss Maintenance Effect of Orlistat in the Treatment of Obesity After a 24 Week Period of Weight Loss by Conventional Diet Therapy, (427414), Hoffmann La Roche Inc, $142,719 (adjustment).
Yogurt Effects on Serum Cholesterol in Humans: A Placebo- Controlled Study, (429238), MONA, $122,235.
Cholesterol - Lowering Effects of Lactobacillus Acidophillus in Rats, (429509), MONA, $8,000.
A Randomized Double-Blind Placebo-Controlled Factorial Design Dose-Response Study of Temocapril HC1 (CS-622) Alone or in Combination with Hydrochlorothiazide in Patients with Mild to Moderate Essential Hypertension, (427753), Parexel International Co, $7,273 (adjustment).
Clinical Protocol Number OMC-GLU-1, (429436), Orphan Medical, $48,615.
A Multicenter, Randomized, Titrate-to Goal Comparison of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolemia (Type Iia & IIb), (428561), Merck and Company Inc, $10,657 (adjustment).
A Multicenter, Randomized, Double-Blind, Titrate-to-Goal Study to Compare the Efficacy fand Tolerability of Simvastatin 10mg, 20mg and 40 mg versus Fluvastatin 20 mg, 40 mg and 49 mg b.i.d. in Patients with Primary Hypercholest,(460091), Merck and Company Inc, $1.
*EtOH a Cofactor in AIDS: Modulation of TH1 and TH2 Cells, (429435), Natl Institute on Alcohol Abuse and Alcoholism, $107,155.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433243), Natl Institute of Neurological Diseases & Stroke, $14,482 (adjustment).
*An Open-Label Study of the Pharmacokinetics of Venlafaxine in Extensive and Poor Metabolizers of Dextromethorphan, (428536), Wyeth Ayerst Research Inc, $44,972 (adjustment).
Immune Mechanisms and Murine Syngeneic GVHD, (425873), Allergy and Infectious Diseases, $113,524 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (433366), Lucille P Markey Charitable Trust, $21,582 (adjustment).
Residency Training in Primary Care Internal Medicine, (428934), Health Professions Bureau, $341,388.
*New Therapeutic Approaches to Breast Cancer, (433348), Natl Cancer Institute, $139,729.
Alcoholic Liver Disease and S-Adenosylmethionine, (429707), Natl Institute on Alcohol Abuse and Alcoholism, $187,697.
*Onmicare Congestive Heart Failure Outcomes Study, (429843), Bristol-Myers Squibb Company, $88,843.
*A Multicenter Pharmacokinetic and Pharmacodynamic Study of Dofetilide in Subjects with Stable Atrial Fibrillation and Reduced Left Ventricular Function, (428192), Pfizer Inc, $42,977 (adjustment).
A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chromic Administration of Vesnarinone in Heart Failure, (428811), Otsuka American Pharmaceutical Inc, $6,387 (adjustment).
Uroguanylin Excretion in Heart Failure Patients and Normal Individuals, (429103), American Heart Assoc KY Affiliate, $15,450.
Serum Amyloid A: Atherogenesis, (428295), Natl Institute on Aging, $170,980 (adjustment). Function of Serum Amyloid A Protein, (429126), Council for Tobacco Research, $75,000.
*A Phase III, Two-Armed, Multi-Center, Randomized, Controlled Comparison of the Efficacy of Cisplatin Plus Etoposide (VP-16) Versus Cisplatin and Tirapazamine in Subjects with Advanced (Stage IIIB and IV) Lung Tumors, (460025), Sanofi Winthrop Inc, $2.
*Phase 3 Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients with Metastatic Non-Small Cell Lung Cancer (Protocol B9E-MC-JHEX), (429627), Eli Lilly and Co, $13,230.
*A Phase III Open-Label, Multicenter Trial of Actimmune Interferon Gamma-1b (rIFN-Y 1b) in Patients with Metastatic Renal Cell Carcinoma, (427692), Genentech Inc, $6,237 (adjustment).
*95-LUN-26US: (WR-53) A Phase III Randomized Study of Intensive Cisplatin and Vinblastine + Amifostine in Patients with Stage III-B or Stage IV Non-Small Cell Lung Cancer, (429447), US Bioscience, $2.
*Phase II, Open-Label Evaluation of 80 ug/kg/day Intravenous Recombinant Human Macrophage Colony-Stimulating Factor (rhM-CSF) for Four 7-Day Treatment Cycles in Patients with Non-Hodgkin's Lymphoma in First or Second Relapse, (427600), Genetics Institute, $5,688 (adjustment).
Selection of Fluoroquinolone-Resistant Staphyloccus Aureus In Vitro: Comparison of LevoFlaxocin and Ciprofloxacin, (429505), Ortho McNeil Pharmaceuticals, $16,875.
*95-NHL-12ID: (Protocol 102-05) Pivotal Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients with Relapsed Low-Grade or Follicular B-Cell Lymphoma, (429034), IDEC Pharmaceuticals Co, $7,999 (adjustment).
*Phase II Study of Chemotherapy with CHOP Followed by ESHAP Chemotherapy in Patients with Intermediate or High Grade Non-Hodgkin's Lymphoma 93-NHL-09, (429482), AMGen, $14,998 (adjustment).
*Anti-Idiotype Vaccine for Breast Cancer, (428687), Natl Cancer Institute, $157,399 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (428693), Lucille P Markey Charitable Trust, $470,000 (adjustment).
*New Therapeutic Approaches to Breast Cancer, (429581), Natl Cancer Institute, $274,246.
*Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Selected Patients with Low-Grade or Follicular B-Cell Lymphoma (IDEC-C2B8 Protocol No. 102-08), (429525), IDEC Pharmaceuticals Co, $2,000.
*American Cancer Society Institutional Research Grant, (429411), American Cancer Society, $60,000.
*Southwest Oncology Group, (429737), Natl Cancer Institute, $38,955.
*Planning Grants for Prospective Cancer Centers, (433332), Natl Cancer Institute, $52,013.
*Planning Grants for Prospective Cancer Centers, (433335), Natl Cancer Institute, $8,820.
*Planning Grants for Prospective Cancer Centers, (433334), Natl Cancer Institute, $51,450.
*Planning Grants for Prospective Cancer Centers, (433333), Natl Cancer Institute, $76,528.
*Planning Grants for Prospective Cancer Centers, (429225), Natl Cancer Institute, $257,250.
The Role of Inflammatory Cytokines in Experimental Acute Pancreatitis, (429107), Glaxo Institute for Digestive Health, $25,000.
African-American Study of Kidney Disease and Hypertension (AASK) (Steering Committee), (429504), Natl Institute Diabetes & Digestive & Kidney, $24,733.
Treatment of Pseudomembranous Colitis by Standard Therapy and Saccharomyces Boulardii Compared with Standard Therapy and Placebo: A Double-Blind Study, (424339), Biocodex Inc, $167,730 (adjustment).
A Phase III Safety and Efficacy Trial of ABT-538 Plus Current Therapy vs Placebo Plus Current Therapy in HIV-Infected Patients, (428932), ClinTrials Research Inc, $190,771 (adjustment).
An International, Double-Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of VIRA MUNE (nevirapine) in Preventing Clinical AIDS Progression Events or Death when used in Combination with 3TC and Stable,(429975), Parexel International Co, $1.
A Phase I Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of 935U83 After Multiple Dosing in Patients with HIV Infection, (428840), Burroughs Wellcome Co, $13,000 (adjustment).
A Long-Term Open-Label Trial Assessing Safety and Tolerance of Chronic Nevirapine Dosing in HIV-1 Infected Patients, (429256), Parexel International Co, $8,788.
Eighteen Month Study In HIV-1 Seropositive Patients To Compare The Efficacy Of MK-639 And Zidovudine Administered Concomitantly To MK-639 Alone And Zidovudine Alone., (429163), Merck and Company Inc, $64,800.
A Phase I/II Trial to Evaluate the Safety Tolerance and Phar Pharmacokinetics of 935U83 in Combination with VIDEX (didanosine) in Patients with HIV Infection, (428606), Burroughs Wellcome Co, $9,998 (adjustment).
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of Less Than 300/mm3, (428251), Upjohn Company, $84,530 (adjustment).
A Phase III Ritonavir Long Term Treatment Trial, (460175), ClinTrials Research Inc, $1.
A Multi-Center, Placebo Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety and Tolerance of: 1) 400mg Nevirapine in Combination with 500-600 mg/day of Zidovudine vs Zidovudine alone in Asymptomatic HIV-1, (427908), Boehringer Ingelheim, $8,866 (adjustment).
Probe Study of the Safety, Tolerability and Immunogencity of an Investigational Formulation of RECOMBIVAX, SP2 (Ultraseed) in Healthy Young Adults, (429569), Merck and Company Inc, $140,000.
A Multiclinic Open-Label Randomized Twenty-Four Week Study To Compare the Safety, Tolberability and Biological Activity of L-735, 524, Zidovudine and Didanosine Administered Concomitantly to L[0735, 524 Alone and Zidovudine and Didano,(428616), Merck and Company Inc, $14,438 (adjustment).
A Double-Blind, Randomized, Dose-Response Study of Three Fixed Doses of Delavirdine Mesylate (U-90152S) in Combination with Zidovudine (ZDV) versus ZDV alone in HIV-1 Infected Individuals with CD4 Counts of 200-500/mm3, (428250), Upjohn Company, $83,530 (adjustment).
A Randomized, Double-Blind, Multicenter Trial Accessing the Safety and Efficacy of a Single Intravenous Dose of CP-116,517 Compared with Cefotetan for the Prophylaxis of infection following Elective Colo-Rectal Surgery, (429047), Natl Medical Research Co, $10,149 (adjustment).
*University of Cincinnati Aids Clinical Trials Unit, (429769), Univ of Cincinnati, $77,984.
A Randomized Multicenter Investigator-Blind Trial Comparing Intravenous CP-116,517 Followed by Oral CP-99,219 with Intravenous Followed by Oral Ciprofloxacin and Ampicillin for Treatment of Community-Acquired Pneumonia, (429743), Pharmaco:LSR, $14,565.
Comparative Study of Cefpodoxime (Vantin) vs. Clarithromycin (Biaxin) in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Smokers, (429744), Pharmacia & Uphohn Inc, $1.
An Open-Label Randomized, Comparative, Multicenter Study of Clinafloxacin Versus a Ceftazideme-Based Regimen in the Treatment of Nosocomial Pnuemonia, (428914), Parke Davis, $9,897 (adjustment).
Double Blind Randomized, Comparative, Multicenter Study of RP64206 (Sparflaxacin) vs Clarithromycin (Biaxin) in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis, (429889), Rhone Poulenc Pharmaceuticals, $1.
Azithromycin in the Treatment of Hospitalized Patients With Community-Acquired Pneumonia.A
Multi-Center Open Comparative Trial Employing Cefuroxime as a Comparative Agent Protocol No. 93-CE33-06185, (427803), Pharmaco LSR, $33,402 (adjustment).
Safety and Immunogenicity in Healthy Adults of an Investigational Formulation of RECOMBIVAX HB (spi) Made From a New Recombinant Master Seed, (425965), Merck Sharp & Dohme Research Laboratories, $1,960 (adjustment).
Revaccination of Healthy Adult Nonresponders to Previous Vaccination with a Licensed Hepatitis B Vaccine Using Hepatitis B Mixed Particle (HBMP) Vaccine or Recombivax HB, (426674), Merck Sharp & Dohme Research Laboratories, $9,200 (adjustment).
Vaccination of Healthy Adults 50-74 Years of Age with 10mcg of Hepatitis B Mixed Particle (HBMP) Vaccine or Recombivax HB, (426702), Merck Sharp & Dohme Research Laboratories, $31,836 (adjustment).
Safety and Immunogenicity of a Two-Dose Regimen of RECOMBIVAX HB (20mcg) in Healthy Adults, (429227), Merck and Company Inc, $110,000 (adjustment).
*A Nonrandomized, Historically Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous and/or Oral Levoflaxin in the Treatment of Chronic Osteomyelitis in Adults, (427035), R W Johnson Pharmaceutical Research Institute, $4,500 (adjustment).
TIMI 12: A Phase II, Multicenter, Randomized, Double-Blind, Aspirin-Controlled Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Tolerability of Ro 48-3657, An Oral Platelet GP llb/llla Antogonist, in Subjects Post an Acute, (429885), Genentech Inc, $1.
Thrombolysis and Thrombin Inhibition in Acute Myocardial Infarctrion (TIMI 9), (428744), Brigham and Womens Hospital, $3,300 (adjustment).
Randomized Trial of Asprin Plus Intravenous Hirudin, Asprin Plus Intravenous Heparin and Asprin Alone in Acute Myocardial Infarction Patients Not Receiving Thrombolytic Therapy, (429437), Brigham and Womens Hospital, $1,000.
Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events, (427034), Sterling Winthrop Research Institute, $9,580 (adjustment).
A Randomized, Double-Blind Evaluation of the Efficacy and Safety of Two Dosing Regimens of Tntegrelin (tm) Vs Placebo for Reducing Mortiality and Myocardial (re) Infarction in Patients with Unstable Angina or Mon-Q-Wave Myocardial Infar,(429792), COR Therapeutics Inc, $1.
A Phase II, Randomized, Open-Label Parallel Group, Multicenter, International Trial of the Safety of TNK-tPA in Acute Myocardial Infarction (Assessment of the Safety of a New Thrombolytic: TNK-tPA [ASSENT]), (429888), Genentech Inc, $1.
A Phase II, Double-Blind, Placebo Controlled Dose-Range and Short-Term Efficacy Study of UP 269-6 in Hypertensive Patients (GHBA_811), (428710), G H Besselaar Associates, $9,639 (adjustment).
Telmisartan 502.214, (429236), Boehringer Ingelheim, $25,512.
Evaluation of the Safety and Comparative Efficacy of Candesartan Cilexetil, Force Titrated from 8 mg Once Daily or 8 mg. BID, in the Treatment of Patients with Hypertension A Multicenter Randomized, Double-Blind, Placebo-Controlled, (429886), Astra Merck Inc, $1.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trail Comparing Valsartan 20 mg, 80 mg, 160 mg and 320 mg to Placebo in Patients with Essential Hypertension Followed By an Open-Label Extension of 52 Weeks Duration, (428560), CIBA GEIGY Co, $7,813 (adjustment).
Faculty Development Program in General Internal Medicine, (428933), Health Professions Bureau, $282,446.
Interleukin-8 and Alcoholic Liver Injury, (428996), Natl Institute on Alcohol Abuse and Alcoholism, $289,822.
Multicenter Efficacy and Tolerability Study Comparing Proscar (finasteride) and Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia in a Primary Care Setting, (427409), ClinTrials Research Inc, $4,725 (adjustment).
*Balloon Angioscope-Development of Aortic Balloon Angioscope and Endovascular Aortic Graft Delivery System, (428838), Baxter Healthcare Co, $40,000 (adjustment).
*94-GU-32PD: (Protocol 1003-01) A Double-Blind, Randomized, Phase 3, Multicenter Study of Suramin Versus Placebo in the Treatment of Patients with Metastatic, Hormone-Refractory Prostate Carcinoma (Stage D2), (429033), Warner Lambert Company, $18,500 (adjustment).
*93-GI-20ZP: An Open, Randomized Multicenter Trial of TOMUDEX " (ZD 1694 Versus 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients with Advanced Colorectal Carcinoma, (427871), Alpha Therapeutic Co, $36,000 (adjustment).
*A Randomized, Double-Blind, Placebo Controlled, Multicenter Evaluation of the Efficacy and Safety of SMS 201-995 pa LAR Given with 5-FU in Comparison to Placebo Given with 5-FU in the Treatment of Patients with Stage III or IV Pancreatic, (429674), Sandoz Pharmaceuticals, $7,447.
*94-LUN-19SW (59075-201) Phase II Open Multicenter Study of Intravenously Administered Tirapazamine plus Cisplatin in Subjects with Previously Untreated Extensive Small Cell Lung Cancer, (428518), Sanofi Winthrop Inc, $22,980 (adjustment).
*94-MISC-46GI(3004) A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with Moderately-High Emetogenic Chemotherapy, (428636), Glaxo Inc, $1,500 (adjustment).
*95-GI-26EL-(Protocol H3E-MC-JMAD) A Phase 2 Trial of LY231514 (Thymidylate Synthase Inhibitor) Administered Intravenously Every 21 Days in Patients with Pancreatic Cancer, (429372), Lily Research Laboratories, $4,500.
*95-GI-25EL-(Protocol H3E-MC-JMAC) A Phase 2 Trial of LY231514 (Thymidylate Synthase Inhibitor) Administered Intravenously Every 21 Days in Patients with Metastatic Colorectal Cancer, (429373), Lily Research Laboratories, $19,125.
*Phase 2 Trial of Gemcitabine Plus Cisplatin Combination Therapy in Chemonaive Patients with Metastatic Urothelial Cancer (Protocol B9E-MC-JHFY), (460023), Eli Lilly and Co, $2.
*94-MISC-43IS: (IMCL CP-9401) Phase Ib/IIa Study of II-6m in Chemotherapy-Induced Thrombocytopenia in Patients with Advanced Malignancies, (428521), ImClone Systems, $20,251 (adjustment).
Studies on Indoor-Allergen Induced Pulmonary Inflammation, (427791), Center for Indoor Air Research, $92,475 (adjustment).
*Role of Milk versus Viral Proteins in the Pathogenesis of Type I Diabetes, (429606), Natl Dairy Council, $68,500.
*Role of Milk versus Viral Proteins in the Pathogenesis of Type I Diabetes, (428975), Natl Dairy Council, $14,671 (adjustment).
Protocol E3A93 - Myeloma Project C: Immunology, (460150), Frontier Science and Technology Research Fdn Inc, $25,171.
*Evaluation of the Role for Multidrug Resistance (MDR) Genes in Normal Human Lymphocyte Function, (428775), Pharmaceutical Manufacturers Assoc Fdtn, $12,500 (adjustment).
*95-MYEL-02ND: (Protocol No. SP-MM-01) A Randomized, Double-Blind, Multicenter Study of Low Dose Gallium Nitrate for Treatment of Bone Involvement Due to Multiple Myeloma, (429446), SoloPak Pharmaceutical Inc, $2,000.
Sequential Evaluation of Tcell Repertrine in Advanced Breast Cancer Patients Undergoing Vaccine Therapy, (429541), Frontier Science and Technology Research Fdn Inc, $13,228.
Fludarabine Enhancement of Human Lymphocyte Cell Function, (429558), Berlex Laboratories, $14,020.
*Structural Prerequisites for Amyloid Fibrillogenesis, (428443), Natl Institute on Aging, $160,301 (adjustment).
Vitamin D Receptor Mapping Intimate Sites of DNA Contact, (427862), Natl Institute Diabetes & Digestive & Kidney, $101,742 (adjustment).
A Double-Blind, Parellel Group, Placebo Controlled, Multi- Centre, Phase IIIA Study to Assess the Safety and Efficacy of Oral Famciclovir (Three times a day and once a day) for the Treatment of Chronic Hepatitis B in Patients with Wild, (429434), Smith Kline Beecham, $3,030.
CV-102-028 Comparison of the Safety and Efficacy of D-L Sotalol in Patients with Life Threatening VT-VF, (427772), Bristol Myers, $275 (adjustment).
*Calcium Regulation in Brain Aging and Alzheimer's Disease, (433290), Natl Institute on Aging, $114,203.
A Randomized, Double-Blind, Parallel, Placebo-Controlled Evaluation of Orally Administered Dofetilide in Patients with Sympomatic Paroxysmal Atrial Fibrillation/Flutter or Paroxysmal Supraventricula Tachycardia, (428268), Pfizer Inc, $30,435 (adjustment).
Randomized Double Blind Placebo Controlled Evaluation of the Efficacy and Safety of Intravenous Administer Dofetilide in Subjects with Spontaneous or Induced Paraoxysmal Supraventricular Tachycardia, (428832), Pfizer Inc, $11,800 (adjustment).
Angeion Implantable Cardioversion/Defibrillator System Clinical Investigation, (429826), Angeion, $1.
Autonomic and Memodynamic Response to Tilt and Isometric Exercise in Patients with Sick Sinus Syndrome, (429783), Pacesetter Inc, $10,346.
A Randomized, Double-Blind, Parallel, Placebo-Controlled Evaluation of Orally Administered Dofetilide in Subjects With Symptomatic Paroxysmal Atrial Fibrillation/Flutter (pAF, pAFL), (429698), Pfizer Inc, $15,000.
An Open-Label Clinical Trial to Assess the Long-Term Safety of Azimilide in Patients with Artial Fibrillation/Flutter and/or Parosysmal Supraventricular Tachycardia, (429603), Procter & Gamble Company, $3,147.
An Double-Blind, Placebo-Controlled, Parallel Design Clinical Trial to Assess the Safety and Efficacy of 100mg of Azimilide for the Prophylactic Treatment of Symptomatic Artrial Fibillation/Flutter and or Syptomatic Parolysmal..., (429604), Procter & Gamble Company, $8,395.
*Immunotherapy and Gene Therapy of Cancer Program, (433297), Lucille P Markey Charitable Trust, $147,879.
*For Your Peace of Mind: A Cervical Cancer Video, (429658), KY Department for Health Services, $9,869.
*For Your Peace of Mind: A Cervical Cancer Video, (429589), Virginia Polytechnic Institute and State Univ, $22,000.
*Sister to Sister Breast and Cervical Cancer Outreach Project, (429805), Natl Alliance of Breast Cancer Organizations, $18,663.
*Brain Vasculature on Leukoaraiosis and Cardiac Surgery, (428584), Wake Forest Univ, $24,530 (adjustment).
22-Oxacalcitriol in Dogs with Experimental Renal Failure, (427071), Chugai Pharmaceutical Company, $109,380 (adjustment).
The Potential Value of Seven New Vitamin D Metabolites in the Prevention and Therapy of Osteoporosis Secondary to Cessation of Ovarian Function, (428169), Hoffmann La Roche Inc, $9,800 (adjustment).
The Effects of 24-Epi-1, 25 Dihydroxyvitamin D2 in the Prevention and Reversal of Bone Loss Occurring After Cessation of Ovarian Function in Experimental Beagle Dogs, (427746), Elan Pharmaceuticals PLC, $25,500 (adjustment).
*Progestogen Effect on Bone and Cognition in Menopause, (433300), Univ of Cincinnati, $76,309.
Protocol # NUCAB3010 A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection Who Are Treatment Naive, (428898), Glaxo Inc, $9,205 (adjustment).
TNF and Mitochondrial Dysfunction in ALD, (429711), Natl Institute on Alcohol Abuse and Alcoholism, $203,119.
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433082), Natl Institute of Neurological Diseases & Stroke, $149,250 (adjustment).
BCL-1: A Cyclin Proto-Oncogene, (428785), Natl Cancer Institute, $75,333 (adjustment).
Consequences of Cyclin D1 Expression in Human B Lymphocytes, (429611), Council for Tobacco Research, $69,575.
Fellowship for J. Wroblewski: Analyses of D Type Cyclins with Monoclonal Antibodies, (429825), Natl Cancer Institute, $31,200.
A Multi-Center, Two-Phase, Prospective, Double-Blind, Randomized Study To Investigate The Safety And Efficacy Of Omeprazole 20mg qd In Comparison To Ranitidine 150mg qid In Relieving Gastro-Esophageal Reflux Disease (GERD) Symptoms, (429331), Pharmaco LSR, $5,451.
A Phase 2 Study to Determine the Safety and Pharmacokinetics and Effective Dose Range and Dosing Duration for Recombinant Activated Protein C (rAPC) in Severe Sepsis, (46), Eli Lilly and Co, $1.
A Multinational, Multicenter, Double Blind, Placebo- Controlled, Phase III Study to Evaluate the Efficacy and Safety of Areosolized Recombinant Human DNASE I in Hospitalized Patients with Chronic Obstructive Pulmonary, (428883), Genentech Inc, $4,200 (adjustment).
A Phase 1, Single Dose Study to Determine the Safety and Pharmacoketics of Affinity Purified Ovine Anti-Tumor Necrosis Factor Alpha (Fab, Lyophilized), (429078), Therapeutic Antibodies, $55,439 (adjustment).
Determination of the Biologically Effective of Maximally Tollerated Dose of Procysteine Injection for the Prevention of Multiple Organ Dysfunction in Subjects with Sepsis Syndrome, (429573), Transcend Therapeutics Inc, $12,247.
Double-blind, Randomized, Placebo Controlled, Parallel-Group Multicenter Study of the Safety Efficacy of Intravenous Taurolidine in Septic Patients, (429161), Wallace Labs, $15,000.
Angiogenesis in Breast Carcinoma -- The Role of Vascular Endothelial Growth Factor, (429534), Ephraim McDowell Cancer Research Fdtn, $25,000.
*Antiestrogens Stop Angigenesis; Potential Mechanisms American Cancer Society Instituional Grant, (433446), American Cancer Society, $10,000.
*A Randomized, Double-Blind, Multicenter Study of Low- Dose Gallium Nitrate for Treatment of Bone Metastases Due to Breast Cancer, (429626), SoloPak Pharmaceutical Inc, $2,000.
*Progestogen Effect on Bone and Cognition in Menopause, (428630), Univ of Cincinnati, $375,925 (adjustment).
LY 307640 vs Ranitidine in the Treatment of Active Duodenal Ulcer Disease, (428829), Pharmaco LSR International Inc, $9,211 (adjustment).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122 311X Compared with GR88502X, Ranitidine and Placebo in Patients With Benign Gastric Ulcer, (426134), Glaxo Inc, $11,530 (adjustment).
LY 307640 vs Placebo: Preventing Relapse in Erosive or Ulcerative Gastroesophageal Reflux Disease, (428830), Pharmaco LSR International Inc, $7,288 (adjustment).
LY 307640 vs Ranitidine in the Treatment of Erosive or Ulcerative Gastroesophageal Reflux Disease, (428828), Pharamco LSR International Inc, $12,467 (adjustment).
*Organization of Myocardial Electrical Activity During Ventricular Fibrillation and Probability of Defibrillation Success: Analysis of Orthogonal Surface Electrocardiograms, (428827), Whitaker Fdtn, $58,596 (adjustment).
Turberculosis Control, (429165), KY Department for Health Services, $12,100.
*A Multi-Center, Open Label, Randomized, Controlled, Phase II Trial Evaluating the Efficacy and Safety of BB-10010 in Patients with Breast Cancer or Malignant Lymphoma Receiving High Dose Etoposide and Cyclophosphamide Chemotherapy, (460024), British Biotech Inc, $2.
Blue Cross/Blue Sheild of Minnesota Research Contract, (429578), Blue Cross Blue Shield of Minnesota, $24,560.
A 12-Week, Double-Blind, Placebo-Controlled Study of Fedotozine in Subjects with Irritable Bowel Syndrome, (429622), Quintiles Inc, $1.
Three Dimensional Echocardiographic Assessment of Ventricular Remodeling Following Acute Myocardial Infarction, (429275), American Heart Assoc KY Affiliate, $12,271.
A Multicenter, Multinational Study to Evaluate the Clinical Utility and Safety of The GenESA System to Diagnose Coronary Artery Disease in Patients With Known or Suspected Coronary Artery Disease, (429724), GENSIA Laboratories, $1.
*TNF and Mitochondrial Dysfunction in ALD, (433428), Natl Institute on Alcohol Abuse and Alcoholism, $9,204.
*Effects of Myocardial Ischemia on B-Receptor Subtype Numbers and Electrophysiologic Response to B2 Receptor Stimulation, (429102), American Heart Assoc KY Affiliate, $18,000.
Phase I/II Trial of Murine Monoclonal Antibody MEDI-500 (T10 B9) in the Treatment of Acute Renal Allograft Rejection, (429837), MedImmune Inc, $10,753.
Trial of a Predictive Algorithem to Transplant High PRA Patients, (429619), Dialysis Clinic Inc, $15,000.
Predictive Algorithm to Transplant High PRA Patients, (429278), Allergy and Infectious Diseases, $157,705.
Analysis of Patient Blood Cytokine Levels During Heart Surgery, (428171), MedImmune Inc, $122,378 (adjustment).
Phase II Trial of Murine Monoclonal Antibody MEDI-500 (T10B9) in the Treatment of Acute Renal Allograft Rejection Single Daily Dose: Part B (10 Day Course), (429835), MedImmune Inc, $8,317.
*Phase II Trial of Murine Monoclonal Antibody MEDI-500 (T10B9) in the Treatment of Acute Renal Allograft Rejection Single Daily Dose: Part A, (429836), MedImmune Inc, $9,298.
A Randomized, Multicenter, Three Month, Double-Blind, Pharmacokinetic, Safety and Tolerability Study of Sandimmune Neoral Soft Gelatin Capsules in Caparison to Sandimmune Soft Gelatin Capsules in Postoperative Primary Renal Transplant, (426950), Sandoz Pharmaceuticals, $3,592 (adjustment).
Praise-2 (Prospective Randomized Amlodipine Survival Evaluation), (429721), Pfizer Inc, $16,635.
*Zinc B12 and Cognitive Decline in the Elderly, (429027), Natl Institute on Aging, $150,070.
A Multi-Center, Double-Blind, Randomized Study to Evaluate the Effects of Ten Day Regimen of Omeprazole a 20mg bid, Clarithromycin 500mg bid and Amoxicillin lgm bid on Eradication of H.pylori and Duodenal Ulcer Healing in Patien,(429887), Astra Merck Inc, $1.
A Placebo Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Active Crohn's Disease, (429237), Centocor Inc, $23,500.
An International Study to Assess Health Related Quality of Life and its Pedictor in Inflamatory Bowel Disease, (429710), Astra Merck Inc, $2,800.
A Randomized, Double-Blind, Placebo-Controlled, Dose- Escalating Study of Recombinant Human Interleukin Eleven (rhIL-11) in Subjects with Active Crohn's Disease, (429473), Genetics Institute, $16,500.
*The Mechanisms of Warfarin Resistance, (429228), American Heart Assoc KY Affiliate, $14,294.
*General Clinical Research Center, (429565), Research Resources, $654,794.
*General Clinical Research Center, (428607), Research Resources, $61,349 (adjustment).
*General Clinical Research Center: Patient Care, (433342), Research Resources, $754,415.
*General Clinical Research Center, Patient Care, (433016), Research Resources, $60,309 (adjustment).
*General Clinical Research Center: Nurses and Dieticians Salaries, (433340), Research Resources, $269,640.
*General Clinical Research Center: Clinical Associate Physician Peter Morris, MD, (433341), Research Resources, $162,533.
*Immunotherapy and Gene Therapy of Cancer Program, (433093), Lucille P Markey Charitable Trust, $235,128 (adjustment).
*Immunotherapy and Gene Therapy of Cancer Program, (433066), Lucille P Markey Charitable Trust, $173,581 (adjustment).
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03